UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 91

Sortiert nach

Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma

Science translational medicine, 2016-06, Vol.8 (341), p.341ra75

2016

Link zum Volltext

Verfügbarkeit prüfen

A short discussion about the SARS-CoV-2 mRNA-1273 vaccine

International journal of infectious diseases, 2021-03, Vol.104, p.532-533

2021

Link zum Volltext

Verfügbarkeit prüfen

Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model

Human gene therapy, 2015-02, Vol.26 (2), p.82

2015

Link zum Volltext

Verfügbarkeit prüfen

Retroviral replicating vector-mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity

Neuro-oncology (Charlottesville, Va.), 2017-07, Vol.19 (7), p.918-929

2017

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer

Cancer gene therapy, 2018-08, Vol.25 (7-8), p.184-195

2018

Link zum Volltext

Verfügbarkeit prüfen

Blockade of type I interferon (IFN) production by retroviral replicating vectors and reduced tumor cell responses to IFN likely contribute to tumor selectivity

Journal of virology, 2014-09, Vol.88 (17), p.10066-10077

2014

Link zum Volltext

Verfügbarkeit prüfen

Retroviral Replicating Vector Delivery of miR-PDL1 Inhibits Immune Checkpoint PDL1 and Enhances Immune Responses In Vitro

Molecular therapy. Nucleic acids, 2017-03, Vol.6, p.221-232

2017

Link zum Volltext

Verfügbarkeit prüfen

A Retroviral Replicating Vector Encoding Cytosine Deaminase and 5-FC Induces Immune Memory in Metastatic Colorectal Cancer Models

Molecular therapy. Oncolytics, 2018-03, Vol.8, p.14-26

2018

Link zum Volltext

Verfügbarkeit prüfen

Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC

Neuro-oncology (Charlottesville, Va.), 2018-09, Vol.20 (10), p.1383-1392

2018

Link zum Volltext

Verfügbarkeit prüfen

Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model

Neuro-oncology (Charlottesville, Va.), 2017-07, Vol.19 (7), p.930-939

2017

Link zum Volltext

Verfügbarkeit prüfen

Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients

Clinical cancer research, 2018-10, Vol.24 (19), p.4680-4693

2018

Link zum Volltext

Verfügbarkeit prüfen

Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with Glioma

Clinical cancer research, 2020-12, Vol.26 (23), p.6176-6186

2020

Link zum Volltext

Verfügbarkeit prüfen

Design and Selection of Toca 511 for Clinical Use: Modified Retroviral Replicating Vector With Improved Stability and Gene Expression

Molecular therapy, 2012-09, Vol.20 (9), p.1689-1698

2012

Link zum Volltext

Verfügbarkeit prüfen

Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector

Neuro-oncology (Charlottesville, Va.), 2012-02, Vol.14 (2), p.145-159

2012

Link zum Volltext

Verfügbarkeit prüfen

Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models

Neuro-oncology (Charlottesville, Va.), 2016-10, Vol.18 (10), p.1390-1401

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1413: Treatment of mouse liver and brain colon cancer metastases with Toca 511 and 5-fluorocytosine for intratumoral production of 5-fluorouracil leads to increased survival, induction of antitumor immune responses, and reduction of MDSC

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.1413-1413

2016

Link zum Volltext

Verfügbarkeit prüfen

PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor models

Oncotarget, 2019-03, Vol.10 (23), p.2252-2269

2019

Link zum Volltext

Verfügbarkeit prüfen

Maintaining therapeutic activity in the operating room: compatibility of a gamma-retroviral replicating vector with clinical materials and biofluids

Molecular therapy. Methods & clinical development, 2014-01, Vol.1 (C), p.14024-14024, Article 14024

2014

Link zum Volltext

Verfügbarkeit prüfen

Inhibition by AICA riboside of gluconeogenesis in isolated rat hepatocytes

Diabetes (New York, N.Y.), 1991-10, Vol.40 (10), p.1259

1991

Link zum Volltext

Verfügbarkeit prüfen

PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor models

Oncotarget, 2019-03, Vol.10 (23), p.2252-2269

2019

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of fatty acid and cholesterol synthesis by stimulation of AMP‐activated protein kinase

The FASEB journal, 1995-04, Vol.9 (7), p.541-546

1995

Link zum Volltext

Verfügbarkeit prüfen

Adenosine kinase inhibitors as a novel approach to anticonvulsant therapy

The Journal of pharmacology and experimental therapeutics, 1999-06, Vol.289 (3), p.1669

1999

Link zum Volltext

Verfügbarkeit prüfen

Toca 511 and Toca FC in patients with gastrointestinal tumors in the Toca 6 study

Journal of clinical oncology, 2018-02, Vol.36 (4_suppl), p.TPS880-TPS880

2018

Link zum Volltext

Verfügbarkeit prüfen

Toca 6: A phase 1b study of Toca 511 and Toca FC in patients with advanced solid tumors or lymphoma

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS2613-TPS2613

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT067: A phase Ib study of Toca 511, a retroviral replicating vector, followed by Toca FC in patients with advanced cancer

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.CT067-CT067

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 91

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(82)
Mit Volltextzugriff
(74)

Publikationsform

Sprache

Englisch
(90)
Japanisch
(16)

Erscheinungsjahr

n.n

Thema

Science & Technology
(47)
Life Sciences & Biomedicine
(42)
Humans
(28)
Animals
(20)
Biological And Medical Sciences
(16)
Male
(14)
Mice
(12)
Medicine, Research & Experimental
(11)
Research & Experimental Medicine
(11)
Female
(10)
Oncology
(10)
Cells, Cultured
(9)
Cytosine Deaminase - Genetics
(9)
Fundamental And Applied Biological Sciences. Psychology
(9)
Aminoimidazole Carboxamide - Analogs & Derivatives
(8)
Medical Sciences
(8)
Rats
(8)
Cell Line
(7)
Cytosine Deaminase
(7)
Disease Models, Animal
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma

A short discussion about the SARS-CoV-2 mRNA-1273 vaccine

Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model

Retroviral replicating vector-mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity

Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer

Blockade of type I interferon (IFN) production by retroviral replicating vectors and reduced tumor cell responses to IFN likely contribute to tumor selectivity

Retroviral Replicating Vector Delivery of miR-PDL1 Inhibits Immune Checkpoint PDL1 and Enhances Immune Responses In Vitro

A Retroviral Replicating Vector Encoding Cytosine Deaminase and 5-FC Induces Immune Memory in Metastatic Colorectal Cancer Models

Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC

Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model

Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients

Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with Glioma

Design and Selection of Toca 511 for Clinical Use: Modified Retroviral Replicating Vector With Improved Stability and Gene Expression

Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector

Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models

Abstract 1413: Treatment of mouse liver and brain colon cancer metastases with Toca 511 and 5-fluorocytosine for intratumoral production of 5-fluorouracil leads to increased survival, induction of antitumor immune responses, and reduction of MDSC

PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor models

Maintaining therapeutic activity in the operating room: compatibility of a gamma-retroviral replicating vector with clinical materials and biofluids

Inhibition by AICA riboside of gluconeogenesis in isolated rat hepatocytes

PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor models

Inhibition of fatty acid and cholesterol synthesis by stimulation of AMP‐activated protein kinase

Adenosine kinase inhibitors as a novel approach to anticonvulsant therapy

Toca 511 and Toca FC in patients with gastrointestinal tumors in the Toca 6 study

Toca 6: A phase 1b study of Toca 511 and Toca FC in patients with advanced solid tumors or lymphoma

Abstract CT067: A phase Ib study of Toca 511, a retroviral replicating vector, followed by Toca FC in patients with advanced cancer

Suchergebnisse filtern